Home
Companies
University of California, Los Angeles

University of California, Los Angeles

Company

Also known as: UCLA

Related News

Studies Find Telemedicine Has Not Increased Costs and Serves Wide Range of Chronic Conditions

May 30, 2026

UCLA-led research finds telemedicine has not significantly increased healthcare visits or costs across all payer types from 2019-2023, published in JAMA Network Open. A separate study of Medicare patients reveals nearly half of telehealth visits are for non-mental health conditions, particularly chronic diseases like diabetes and high blood pressure. Both findings address questions about telehealth's role and impact since the COVID-19 pandemic.

CAR-NK and CAR-NKT Cell Therapies Show Promise Across Multiple Cancer Types

May 22, 2026

A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.

Nanoparticle gene editing restores CFTR function in cystic fibrosis lab model

Apr 25, 2026

Researchers developed a lipid nanoparticle gene-editing approach that inserted a full CFTR gene into airway cells and restored 88% to 100% of normal channel function in a cystic fibrosis lab model.

CRISPR Gene Editing Advances in Heart Failure, Cystic Fibrosis, and Cholesterol Treatment

Mar 09, 2026

Three new CRISPR-based therapies show promise for treating heart failure through mitochondrial enhancement, cystic fibrosis via lipid nanoparticle gene insertion, and elevated cholesterol with single-dose gene editing targeting ANGPTL3.

Nanoparticle Gene Editing Offers New Hope for Cystic Fibrosis Patients

Mar 02, 2026

UCLA scientists developed a lipid nanoparticle-based gene editing system that successfully inserts a full-length healthy CFTR gene into human airway cells, offering potential treatment for cystic fibrosis patients unresponsive to current therapies.

Immunotherapy Plus Chemotherapy Before Surgery Shows Promise for Pancreatic Cancer

Feb 18, 2026

A UCLA clinical trial found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing deep, durable responses including complete tumor regression.

Lipid Nanoparticles Deliver Full CFTR Gene in Cystic Fibrosis Gene Therapy Advance

Feb 18, 2026

UCLA researchers developed lipid nanoparticle-based gene editing that inserts a complete CFTR gene into human airway cells, restoring up to 100% of normal channel function in cystic fibrosis laboratory models without viral vectors.

Trethera Announces Clinical Progress for TRE-515 Cancer and Autoimmune Drug

Feb 12, 2026

Trethera Corporation completed Phase 1 solid tumor dose escalation trial for TRE-515 and received FDA Fast Track designation for prostate cancer and Orphan Drug status for two autoimmune neurologic diseases.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07613398	An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function	NOT_YET_RECRUITING
NCT07605598	Measuring Pelvic Floor Muscle Fitness Before and After Treatment	NOT_YET_RECRUITING	NA
NCT07600697	Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery	NOT_YET_RECRUITING	PHASE4
NCT07599592	Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor	RECRUITING	EARLY_PHASE1
NCT07581327	Data-Driven Lay First Responder Program in Cameroon	NOT_YET_RECRUITING	NA
NCT07577947	Health And Response: Digital Markers for Outcomes in Perinatal Depression Treatment Study	NOT_YET_RECRUITING	NA
NCT07577401	Calming Minds Study	NOT_YET_RECRUITING	NA
NCT07568119	Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care	ACTIVE_NOT_RECRUITING
NCT07566104	Group PACBT for Depression	NOT_YET_RECRUITING	PHASE2
NCT07534696	Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy	ENROLLING_BY_INVITATION	NA